Selinexor Approved for R/R Diffuse Large B-Cell Lymphoma

Accelerated approval was granted to selinexor (Xpovio®, Karyopharm Therapeutics) to treat adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL), including those with DLBCL resulting from follicular lymphoma, after receiving at least two prior lines of systemic therapy. Selinexor had previously been approved in combination with dexamethasone for adult patients with R/R multiple myeloma who were previously treated with at least four therapies and whose disease is refr...
Continue reading

Ibrutinib Plus R-CHOP for Non-Germinal Center DLBCL With Wyndham Wilson, MD

Diffuse large B-cell lymphoma (DLBCL), the most common subtype of non-Hodgkin lymphoma, has a 5-year survival rate of 63%. However, patients with non-germinal center B-cell-like (non-GCB) disease and high MYC and BCL2 expression face a poorer prognosis, with limited treatment options. In the phase 3 PHOENIX trial, Wyndham Wilson, MD, the Head of the Lymphoma Therapeutics Section at the National Cancer Institute, and colleagues investigated a combination of ibrutinib and rituximab, cyclophosphami...
Continue reading

Polatuzumab Vedotin Approved in Relapsed/Refractory DLBCL

The FDA has now granted accelerated approval to polatuzumab vedotin (Polivy®, Genentech, Inc.) in combination with bendamustine and a rituximab product for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, following two or more prior lines of therapy. Estimates of five-year survival for DLBCL have been reported at 62.0% in the United States and 55.4% in Europe. Over 50% of patients with advanced-stage, previously untreated DLBCL experience complet...
Continue reading

Rituximab/Lenalidomide/Ibrutinib Effective in DLBCL

A phase 2 study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting revealed that a combination of rituximab (Rituxan®, Genentech USA, Inc), lenalidomide (Revlimid®, Celgene Corporation), and ibrutinib (Imbruvica®, Janssen Biotech, Inc) demonstrates overall response in adult patients with previously untreated non-germinal center B-cell (non-GCB)–like subtype diffuse large B-cell lymphoma (DLBCL). Rituximab, which targets abnormal B cells and reduces their lifespan, is al...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.